$ICLR

McCague Eugene Pacelli sold $138K of ICLR

McCague Eugene Pacelli sold 841 shares of ICON PLC (ICLR) at an average of $164.29 ($162.72–$165.51, $0.14M total) across 4 trades on 2026-08-11.

Original reporting
SEC EDGAR · McCague Eugene Pacelli
Published Aug 12, 2026, 8:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ICLR
Neutral
medium confidence
Mentioned
$ICLR
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICLRNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale details and post-transaction holdings (3,811 shares). This is primarily a sentiment/positioning datapoint rather than a fundamental update.

02

Market read

Traders may note the insider sale for sentiment, but there is no accompanying guidance, contract, or operational catalyst in the text.

03

What to watch

The article provides no context on why the sale occurred (taxes, diversification, planned liquidity needs) and no concurrent company disclosures, limiting inference quality.

Relevance 4/10Novelty 3/10Timing: Filed on 2026-08-12, covering sales executed on 2026-08-11.

Background

The article is a SEC Form 4 insider transaction disclosure for ICON PLC, reported by director McCague Eugene Pacelli.

Company-level read

Ticker impact

$ICLRNeutralMedium confidence
Context

ICON PLC director McCague Eugene Pacelli sold about 841 shares in open-market trades at $162.72 to $165.51, totaling $138,167.75.

Expected impact

Limited, if any, near-term price impact; any effect is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with a modest dollar value and no stated 10b5-1 plan, but insider sales are common and not, by themselves, a fundamental catalyst.

Market effects

No clear sector read-through from a single director sale without accompanying company-specific operational or financial news.

None indicated.

None indicated.

Counterpoint

Because the sale was not under a 10b5-1 plan, it could reflect timing discretion rather than routine liquidity, potentially warranting closer monitoring of subsequent insider activity.

Key entities

  • ICON PLC

    Company whose director insider sale is disclosed on Form 4.

  • McCague Eugene Pacelli

    Director who sold 841 shares across four trades on 2026-08-11.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICLRMedAI 9/10

ICON plc: ICON Reports Second Quarter 2026 Results

ICON plc (NASDAQ: ICLR) reported Q2 2026 results. Revenue was $2,063.5 million, up 1.4% QoQ. Adjusted EBITDA was $327.2 million (15.9% of revenue). GAAP net income was $72.6 million ($0.94 diluted EPS) and adjusted net income was $198.4 million ($2.56 adjusted EPS). Net business wins were $3,120 million, backlog $23.4 billion, and it reaffirmed 2026 guidance.

$ICLRHighAI 8/10

ICON PLC (ICLR): Financial results for Q2 2026

ICON PLC (ICLR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ICON Reports Second Quarter 2026 Results Highlights • Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. • Quarter two adjusted EBITDA of $327.2 million or 15.9% of revenue, an increase of 3.0% on quarter one 2026. • GAAP net income for

$ICLRMed

ICON stock surges 7% on Anthropic AI partnership for trials By Investing.com

ICON plc (NASDAQ:ICLR) shares rose about 7.8% after the company announced a multi-year partnership with Anthropic to integrate Claude AI into its Orbis clinical trial platform. ICON said the collaboration will add four production capabilities, including site intelligence and enrollment risk detection, and will roll out Claude across roles. ICON cited enrollment delays affecting up to 80% of trials.

$ICLRMed

ICON, Anthropic Sign Multi-Year Partnership Deal To Advance AI Capabilities, Stock Up In Pre-Market

ICON Public Limited Company (ICLR) said it signed a multi-year partnership with Anthropic to integrate Claude AI across the clinical trial lifecycle using ICON’s Orbis platform. ICON plans to work with Anthropic’s life sciences team and deploy Claude Code, Claude, and Claude Science. The company cited CEO Barry Balfe. In pre-market, ICLR rose to $177.69, up 5.28% on Nasdaq.